Stefani A. Westerberg, NPC

Stefani Westerberg practices at Saint Alphonsus Regional Medical Center in Boise, Idaho, part of Trinity Health.

Stefani Westerberg's NPI, 1417256736, was assigned on March 25, 2011. Stefani Westerberg holds Idaho license NP1045A.

Stefani Westerberg's primary practice is Saint Alphonsus Regional Medical Center, at 1055 North Curtis Road, Boise, ID 83706 in Ada County. The practice phone is (208) 367-2121.

Stefani Westerberg's primary practice is Saint Alphonsus Regional Medical Center in Boise, Idaho, part of Trinity Health. The medical group on file is Saint Alphonsus Regional Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Stefani Westerberg practices. Vendor and product names are available with a free account.

Hospitalist is Stefani Westerberg's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Stefani Westerberg is licensed in Idaho.

CMS data shows 140 Medicare services from Stefani Westerberg across 2 procedure codes in 2024, for 120 Medicare patients. Medicare paid $6,369 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 120 Medicare patients who saw Stefani Westerberg in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have arthritis, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Stefani Westerberg's median patient age at 76, with 78% women.

In 2024, Stefani Westerberg wrote 96 Medicare Part D claims for 38 patients. 95% of them were for generic drugs. CMS names the drug for 52 of them, across 3 drugs with 11 or more claims each, at $845 in total drug cost. In 2023, CMS named 58 claims across 4 drugs.

Stefani Westerberg accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 25 general payments to Stefani Westerberg from 4 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Revance Therapeutics, Inc. paid the most, $348.